

Larubrilstat
CAS 2765226-31-9
MF C21H25N5O2 MW379.5 g/mol
[2-[[(5R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl]amino]pyrimidin-5-yl]-(8-oxa-2-azaspiro[4.5]decan-2-yl)methanone
- [2-[[(5R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl]amino]pyrimidin-5-yl]-(8-oxa-2-azaspiro[4.5]decan-2-yl)methanone
- Methanone, [2-[[(5R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl]amino]-5-pyrimidinyl]-8-oxa-2-azaspiro[4.5]dec-2-yl-
(2-{[(5R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl]amino}pyrimidin-5-yl)(8-oxa-2-azaspiro[4.5]decan-2-
yl)methanone
vascular non-inflammatory molecule-1 (VNN1) inhibitor, AG6K4Y29B4
Larubrilstat is the International Nonproprietary Name (INN) for an experimental, small-molecule vascular non-inflammatory molecule-1 (VNN1) inhibitor. VNN1, also commonly known as Vanin-1 or pantetheinase, is an enzyme involved in tissue response to oxidative stress and inflammation.
Current Status
- Development Context: Larubrilstat is a designated compound linked to therapeutic exploration in inflammatory pathways. Research and patent filings, such as those cataloged by the IUPHAR/BPS Guide to PHARMACOLOGY, track its evaluation alongside similar Vanin-1 inhibitors
SYN
https://patentscope.wipo.int/search/en/detail.jsf?docId=US425298584&_cid=P20-MQHGA8-93141-1
COMP 2-1 IS PRODUCT
Example 2: Synthesis of Compound 2, Compound 2-1 and Compound 2-2

| Step 1 |
Step 2
Step 3
| Compound 2 (66 mg) was obtained from compound if (168 mg) and compound 2c (100 mg) according to the method of Example 1. |
| Two enantiomers 2-1 (retention time: 8.483 min) and 2-2 (retention time: 13.580 min) were obtained by chiral separation of compound 2. |

Step 4: Preparation of Compound 2-1
| The absolute stereochemical configuration of compound 2-1 was determined by comparative determination of the above preparation method of the chiral compounds. |
PAT

ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma



AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE

join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com

PAT
- Pyrimidine carboxamide compound and application thereofPublication Number: US-2024083873-A1Priority Date: 2020-09-25
- Pyrimidine carboxamide compound and application thereofPublication Number: WO-2022063197-A1Priority Date: 2020-09-25
- Pyrimidine carboxamide compound and application thereofPublication Number: WO-2022063333-A1Priority Date: 2020-09-25
////////larubrilstat, ANAX LABS, vascular non-inflammatory molecule-1 (VNN1) inhibitor, AG6K4Y29B4
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
